Vaccine (Peptide vaccine) · Immune activation, directed at patient-specific tumor neoantigens · developed by Evaxion Biotech
EVX-01 is a personalized liposomal peptide vaccine made of patient-specific neoepitopes derived from tumor-associated antigens. The neoepitopes are designed to induce cytotoxic T-lymphocyte responses against tumor cells expressing these antigens. It is being studied in combination with standard of care for unresectable or stage IV melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05309421 | Phase 2 | Melanoma Stage IV | Completed | EVAX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Melanoma Stage IVUnresectable Melanoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the EVAX page.
See EVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EVAX catalysts and pipeline →